Synthesis of Radiolabeled and Stable‐Isotope Labeled Deucravacitinib (BMS‐986165)

ABSTRACT Deucravacitinib (BMS‐986165) is a small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) currently approved for the treatment of moderate to severe plaque psoriasis. Tyrosine kinase 2 (TYK2) is a member of the Janus (JAK) family of non‐receptor kinases that modulate the production of inflammatory cytokines. The synthesis of 14 C‐radiolabeled and stable‐isotope labeled variants of deucravacitinib is described in this publication.